214 related articles for article (PubMed ID: 8460648)
1. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology.
Lin HJ; Han CY; Lin BK; Hardy S
Am J Hum Genet; 1993 Apr; 52(4):827-34. PubMed ID: 8460648
[TBL] [Abstract][Full Text] [Related]
2. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene.
Lin HJ; Han CY; Lin BK; Hardy S
Pharmacogenetics; 1994 Jun; 4(3):125-34. PubMed ID: 7920692
[TBL] [Abstract][Full Text] [Related]
3. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans.
Bell DA; Taylor JA; Butler MA; Stephens EA; Wiest J; Brubaker LH; Kadlubar FF; Lucier GW
Carcinogenesis; 1993 Aug; 14(8):1689-92. PubMed ID: 8102597
[TBL] [Abstract][Full Text] [Related]
4. Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese.
Chan DK; Lam MK; Wong R; Hung WT; Wilcken DE
Neurology; 2003 Mar; 60(6):1002-5. PubMed ID: 12654968
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population.
Agúndez JA; Martínez C; Olivera M; Ledesma MC; Ladero JM; Benítez J
Clin Pharmacol Ther; 1994 Aug; 56(2):202-9. PubMed ID: 8062497
[TBL] [Abstract][Full Text] [Related]
6. Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol.
Rodriguez JW; Kirlin WG; Ferguson RJ; Doll MA; Gray K; Rustan TD; Lee ME; Kemp K; Urso P; Hein DW
Arch Toxicol; 1993; 67(7):445-52. PubMed ID: 7902079
[TBL] [Abstract][Full Text] [Related]
7. [The acetylator polymorphism in a Khmer population: clinical consequences].
Bechtel YC; Bechtel PR; Lelouët H; Choisy H; Dy NR
Therapie; 2001; 56(4):409-13. PubMed ID: 11677864
[TBL] [Abstract][Full Text] [Related]
8. Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis.
Woolhouse NM; Qureshi MM; Bastaki SM; Patel M; Abdulrazzaq Y; Bayoumi RA
Pharmacogenetics; 1997 Feb; 7(1):73-82. PubMed ID: 9110365
[TBL] [Abstract][Full Text] [Related]
9. Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients.
Agúndez JA; Ladero JM; Olivera M; Abildúa R; Román JM; Benítez J
Oncology; 1995; 52(1):7-11. PubMed ID: 7800347
[TBL] [Abstract][Full Text] [Related]
10. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations.
Deloménie C; Sica L; Grant DM; Krishnamoorthy R; Dupret JM
Pharmacogenetics; 1996 Apr; 6(2):177-85. PubMed ID: 9156695
[TBL] [Abstract][Full Text] [Related]
11. Cloning, expression, and functional characterization of two mutant (NAT2(191) and NAT2(341/803)) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles.
Ferguson RJ; Doll MA; Rustan TD; Gray K; Hein DW
Drug Metab Dispos; 1994; 22(3):371-6. PubMed ID: 7915226
[TBL] [Abstract][Full Text] [Related]
12. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population.
Mrozikiewicz PM; Cascorbi I; Brockmöller J; Roots I
Clin Pharmacol Ther; 1996 Apr; 59(4):376-82. PubMed ID: 8612380
[TBL] [Abstract][Full Text] [Related]
13. Lung cancer and mutations at the polymorphic NAT2 gene locus.
Martínez C; Agúndez JA; Olivera M; Martín R; Ladero JM; Benítez J
Pharmacogenetics; 1995 Aug; 5(4):207-14. PubMed ID: 8528267
[TBL] [Abstract][Full Text] [Related]
14. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.
Hein DW; Doll MA; Rustan TD; Gray K; Feng Y; Ferguson RJ; Grant DM
Carcinogenesis; 1993 Aug; 14(8):1633-8. PubMed ID: 8353847
[TBL] [Abstract][Full Text] [Related]
15. Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens.
Fretland AJ; Doll MA; Gray K; Feng Y; Hein DW
Toxicol Appl Pharmacol; 1997 Feb; 142(2):360-6. PubMed ID: 9070359
[TBL] [Abstract][Full Text] [Related]
16. Purification of hepatic polymorphic arylamine N-acetyltransferase from homozygous rapid acetylator inbred hamster: identity with polymorphic N-hydroxyarylamine-O-acetyltransferase.
Trinidad A; Hein DW; Rustan TD; Ferguson RJ; Miller LS; Bucher KD; Kirlin WG; Ogolla F; Andrews AF
Cancer Res; 1990 Dec; 50(24):7942-9. PubMed ID: 2253236
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations.
Xie HG; Xu ZH; Ou-Yang DS; Shu Y; Yang DL; Wang JS; Yan XD; Huang SL; Wang W; Zhou HH
Pharmacogenetics; 1997 Dec; 7(6):503-14. PubMed ID: 9429236
[TBL] [Abstract][Full Text] [Related]
18. Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis.
Skretkowicz K; Skretkowicz J; Gawrońska-Szklarz B; Górnik W; Rychlik-Sych M; Sysa-Jedrzejowska A
Eur J Clin Pharmacol; 2005 Jan; 60(11):773-8. PubMed ID: 15565348
[TBL] [Abstract][Full Text] [Related]
19. Acetylation polymorphism and prevalence of colorectal adenomas.
Probst-Hensch NM; Haile RW; Ingles SA; Longnecker MP; Han CY; Lin BK; Lee DB; Sakamoto GT; Frankl HD; Lee ER
Cancer Res; 1995 May; 55(10):2017-20. PubMed ID: 7743494
[TBL] [Abstract][Full Text] [Related]
20. Variation of the N-acetyltransferase 2 gene in a Romanian and a Kyrgyz population.
Rabstein S; Unfried K; Ranft U; Illig T; Kolz M; Rihs HP; Mambetova C; Vlad M; Brüning T; Pesch B
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):138-41. PubMed ID: 16434599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
